
Biotech IPO Window Reopens, But M&A Remains Strong, JPMorgan Execs Say
The IPO window for biotech companies is open, but strong firms may still opt for M&A with Big Pharma. Investors are selective, favoring 'best in class' assets. Deal values are increasing, with China emerging as a key player.
















